Skip to main content
Sign inSign up

ADSA Society

IssuesFor AuthorsAdvertisingNewsHelp

ADSA Society

Article Contents

Download PDF

First described in 1956 subsequent to a reaction reported to the newly introduced antipsychotic drug chlorpromazine, neuroleptic malignant syndrome (NMS) is a rare, potentially life-threatening reaction to antipsychotic drugs characterized by high fever, muscle rigidity, altered mental status, and autonomic instability. All neuroleptics, including newer antipsychotics, have been linked to this condition. Due to similar symptoms, it is debatable if individuals with NMS can be susceptible to malignant hyperthermia (MH). This case report presents the anesthetic care of a 30-year-old male undergoing general anesthesia in the office-based dental environment. The rationale behind the selected total intravenous anesthesia technique without NMS or MH triggering agents is outlined as well as other agents that may still be questionable regarding their trigger effect for NMS.

Keywords: Neuroleptics; Neuroleptic malignant syndrome; Malignant hyperthermia; General anesthesia
  • Download PDF
Copyright: © 2023 by the American Dental Society of Anesthesiology

Get Email Alerts

Article Contents
ANPR logo
AboutIssuesAuthor InformationSubscriptions

ADSA Society

eISSN: 1878-7177

ISSN: 0003-3006

Powered by PubFactory